BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31121484)

  • 1. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
    Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
    Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q; Wang Y; He J
    J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
    Jiao P; Hou J; Yao M; Wu J; Ren G
    Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
    Ma G; Zhu J; Liu F; Yang Y
    DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.
    Li X; Zhang X; Yang C; Cui S; Shen Q; Xu S
    Cell Cycle; 2018; 17(14):1772-1783. PubMed ID: 30010468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
    Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
    Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
    Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
    J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.
    Tang Q; Zhou Q; Li J; Yang X; Wang R; Wang X; Xu M; Han L; Wu W; Wang S
    Carcinogenesis; 2023 Aug; 44(6):497-510. PubMed ID: 37144780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1.
    Zhang T; Wang N
    Oncol Res; 2018 Sep; 26(8):1191-1200. PubMed ID: 29386087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.
    Yang T; Li H; Chen T; Ren H; Shi P; Chen M
    Mol Cells; 2019 Mar; 42(3):270-283. PubMed ID: 30841025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
    Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
    BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
    Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
    J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.
    Wang C; Ding S; Sun B; Shen L; Xiao L; Han Z; Huang H
    Pharmacol Res; 2020 Nov; 161():105110. PubMed ID: 32755614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA SNHG14 exerts oncogenic functions in non-small cell lung cancer through acting as an
    Zhang Z; Wang Y; Zhang W; Li J; Liu W; Lu W
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30254102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
    Zhou YM; Liu J; Sun W
    Asian Pac J Cancer Prev; 2014; 15(3):1391-6. PubMed ID: 24606471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.